Phase III trial of telatinib in combination with a standard chemotherapy regimen for advanced gastric cancer

Trial Profile

Phase III trial of telatinib in combination with a standard chemotherapy regimen for advanced gastric cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Antineoplastics; Telatinib
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2011 The FDA has approved the design of this trial under a Special Protocol Assessment.
    • 28 Feb 2011 ACT Biotech has filed a Special Protocol Assessment (SPA) with the US FDA for this trial, according to an ACT Biotech media release.
    • 13 Oct 2010 ACT Biotech is on track to file for marketing approval in the USA and Europe in 2014, according to a ACT Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top